Reporting Process

*New Reporting Process
As of July 26, 2024, a new process for reporting subsequent infusions was implemented.

The Indication for CIBMTR Data Reporting (2814) Form collects information to initiate CIBMTR reporting on the appropriate research or data collection forms. This form must be completed for the first indication requiring the individual to register for a CIBMTR Research ID (CRID) and any subsequent infusions the recipient received.

• First infusions: This is the first form completed after the CIBMTR Research ID Assignment (2804) Form.
• Subsequent infusions: This form is triggered from the Post-Transplant Essential Data (2450), Post-HCT Follow-up Data (2100), or Post-Cellular Therapy Essential Data (4100) forms when a subsequent infusion is reported.

!Subsequent Infusions and Cellular Therapy Essential Data Pre-Infusion (4000) Made ‘NRQ’
If the subsequent infusion is a cellular therapy and a center needs the F4000 to be made NRQ, first complete the F2814, triggering the F4000, and then submit a request via CIBMTR Center Support.

On-Demand reporting
There are two appropriate scenarios where centers should create an on-demand Form 2814:

1. To report a subsequent infusion when there are NO follow up forms (F2100, F2450 or F4100) available to report this information.

!On -Demand Reporting vs Reporting On Forms Due
If follow-up forms are DUE in the forms grid, centers should NOT create a F2814, but report the subsequent infusion on the applicable follow-up form.

2. To report DLIs “on time”

For steps on how to create an on-demand form, see ‘Create an Unscheduled Form’ within the FormsNet3^SM Training Guide.

The combination of answers provided in this form is used to determine the infusion type and which forms are required. Refer to Tables 1 and 2 for reference.

Event date
If the form is in DUE status, the event date displayed in the Recipient Forms Grid will be the date the form was created. When the form is submitted, the event date will update to the infusion date provided on the form (for HCT, gene therapy, or cellular therapy) or it will be updated to the appropriate allogeneic HCT event date for DLIs.

Determination of Infusion Type and Forms Required
The combination of answers provided will determine the infusion type (HCT, gene therapy, cellular therapy or DLI). Review the tables below to understand how the infusion type is determined, and which forms are required.

Table 1. Reporting HCTs and Gene Therapies

Table 2. Reporting Cell Therapies

Form Submission Message
When the Form 2814 is submitted, a message will display showing the infusion type.

The infusion type will also display in the Recipient Forms Grid in the Visit Details column.

Editing the F2814
This form can be edited until the Pre-TED (2400) and Disease Classification (2402) Forms or Pre-CTED (4000) Form is completed and submitted.

If the infusion type displayed on the form completion page or in the Visit Details column of the Recipient forms grid is incorrect, go back and edit the form. Refer to Table 1 and 2 to understand how the infusion type is determined

If any changes to the form need to be made after these forms are submitted, contact CIBMTR Center Support .

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.